3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,662 as of Friday, May 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,201 issues advancing vs. 1,742 declining with 169 unchanged.

The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Alexion Pharmaceuticals ( ALXN), down 1.9%, Illumina ( ILMN), down 1.8%, Valeant Pharmaceuticals International ( VRX), down 1.5%, Shire ( SHPG), down 1.3% and Actavis ( ACT), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Vertex Pharmaceuticals is down $1.05 (-1.4%) to $71.76 on light volume. Thus far, 464,943 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $71.33-$72.96 after having opened the day at $72.96 as compared to the previous trading day's close of $72.81.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $16.9 billion and is part of the health care sector. Shares are down 2.0% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is down $0.77 (-0.7%) to $115.23 on light volume. Thus far, 776,837 shares of Amgen exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $115.03-$116.57 after having opened the day at $116.57 as compared to the previous trading day's close of $116.00.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $87.6 billion and is part of the health care sector. Shares are up 1.7% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $1.01 (-1.2%) to $81.07 on light volume. Thus far, 4.2 million shares of Gilead exchanged hands as compared to its average daily volume of 17.0 million shares. The stock has ranged in price between $81.05-$82.10 after having opened the day at $81.77 as compared to the previous trading day's close of $82.08.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $125.7 billion and is part of the health care sector. Shares are up 9.3% year-to-date as of the close of trading on Thursday. Currently there are 17 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb